The global custom antibody market size reached USD 175.70 million in 2023 and is projected to surpass around USD 444.66 million by 2033 with a significant CAGR of 9.73% from 2024 to 2033.
Key Points
- The North America custom antibody market size reached USD 80.82 million in 2023 and is expected to attain around USD 206.77 million by 2033, poised to grow at a CAGR of 9.84% between 2024 and 2033.
- North America dominated the market with the largest revenue share of 46% in 2023.
- Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033.
- By type, the monoclonal antibodies segment has contributed more than 51% of revenue share in 2023.
- By type, the recombinant antibodies segment is expected to grow at a soldi CAGR of 11.93% during the forecast period.
- By service, the antibody development segment has held a major revenue share of 55% in 2023.
- By source, the rabbit segment has recorded more than 50% of revenue share in 2023.
- By source, the mice segment is estimated to be the fastest-growing during the forecast period.
- By application, the infectious disease segment has generated more than 28% of revenue share in 2023.
- By application, the oncology segment is the fastest-growing during the forecast period.
- By end-use, the academic research & institutes segment dominated has captured the biggest revenue share of 58% in 2023.
- By end-use, the pharmaceutical & biotechnology companies segment is the fastest-growing during the forecast period.
Type
The Custom Antibody Market includes both monoclonal and polyclonal antibodies. Monoclonal antibodies are derived from a single clone of cells and offer high specificity, making them ideal for targeted therapies and diagnostic applications requiring precise antigen recognition. Polyclonal antibodies, derived from multiple clones of cells, recognize multiple epitopes on an antigen, providing broader applications in techniques like Western blotting and immunohistochemistry.
Service
Services in the Custom Antibody Market encompass antibody production, purification, conjugation, and validation. Antibody production involves generating antibodies against specific antigens using techniques like hybridoma technology or recombinant DNA technology. Purification ensures the isolation of high-quality antibodies, while conjugation involves attaching molecules such as enzymes or fluorophores for various labeling and detection purposes. Validation confirms antibody specificity, affinity, and functionality through assays like ELISA and immunohistochemistry.
Source
Custom antibodies can be sourced from various organisms, including rabbits, mice, goats, and recombinant sources. Traditional sources such as rabbits and mice provide polyclonal antibodies through immunization protocols. Recombinant sources utilize engineered cells to produce antibodies with predefined characteristics, enhancing customization and scalability in biomanufacturing processes.
Application
Custom antibodies are widely applied in research, diagnostics, and therapeutics. In research, they facilitate protein characterization, biomarker discovery, and pathway analysis. Diagnostically, custom antibodies are pivotal for disease detection and monitoring through assays like ELISA and flow cytometry. Therapeutically, they are employed in targeted therapies for conditions such as cancer and autoimmune diseases, enhancing treatment efficacy while minimizing adverse effects on healthy tissues.
End-use
The Custom Antibody Market serves diverse end-users including academic and research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and contract research organizations (CROs). Academic institutions utilize custom antibodies for fundamental research and development of novel treatments. Pharmaceutical and biotechnology firms integrate custom antibodies into drug discovery and development pipelines, while diagnostic labs rely on them for accurate disease diagnosis and patient management.
Custom Antibody Market Companies
- GenScript
- LifeSpan BioSciences, Inc
- Labcorp Drug Development
- Abmart
- YenZym Antibodies, LLC.
- Kaneka Eurogentec S.A.
- Bio-Rad Laboratories, Inc
- Abcam plc
- Creative Diagnostics
- Thermo Fisher Scientific Inc.
Recent Developments
- In October 2022, Absolute Biotech Company launched to offer antibody reagents, services, and expertise to researchers worldwide for therapeutic, diagnostic, and research applications. The company offers recombinant antibody expression, antibody engineering, custom antibody sequencing services, and more than one million off-the-shelf life science reagents.
- In March 2024, a leading biotechnology company in genetic medicine, Agathos Biologics, launched its rAAV (recombinant adeno-associated virus) production service by using the company’s new AE1-BHK cell line. The company recorded its first sale of rAAV to a CRO/CMO (contract research and manufacturing organization), Genovac, that discovers, manufactures, and develops antibodies for research, therapeutics, and diagnostics market segments.
Segments Covered in the Report
By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
- Others
By Service
- Antibody Development
- Antibody Production & Purification
- Antibody Fragmentation & Labeling
By Source
- Mice
- Rabbit
- Others
By Application
- Oncology
- Infectious Diseases
- Neurology
- Stem Cells
- Immunology
- Cardiovascular Diseases
- Others
By End-use
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CRO
- Hospitals and Clinics
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/